HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.
about
HIV-1 integrase inhibitor resistance and its clinical implicationsImpact of human immunodeficiency virus type-1 sequence diversity on antiretroviral therapy outcomesUnprocessed viral DNA could be the primary target of the HIV-1 integrase inhibitor raltegravirDevelopment of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutationsProlonged and substantial discordance in prevalence of raltegravir-resistant HIV-1 in plasma versus PBMC samples revealed by 454 "deep" sequencingHIV-1 genetic variation and drug resistance development.Resistance to integrase inhibitors.In vitro evolution of an HIV integrase binding protein from a library of C-terminal domain γS-crystallin variants.HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland.Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor.3-Hydroxypyrimidine-2,4-diones as an inhibitor scaffold of HIV integraseIn vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2MK-0536 inhibits HIV-1 integrases resistant to raltegravirPopulation pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individualsA Novel Class of HIV-1 Antiviral Agents Targeting HIV via a SUMOylation-Dependent Mechanism.Binding mode prediction of biologically active compounds from plant Salvia Miltiorrhiza as integrase inhibitor.3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides Potently Inhibit HIV-1 Integrase and RNase H.Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir.Novel integrase inhibitors for HIV.Raltegravir as antiretroviral therapy in HIV/AIDS.Elvitegravir: a review of its use in adults with HIV-1 infection.Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection.Longitudinal analysis of integrase N155H variants in heavily treated patients failing raltegravir-based regimens.Different Pathways Leading to Integrase Inhibitors ResistanceThe SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypes.Prospective strategies for targeting HIV-1 integrase function.Impact of the HIV integrase genetic context on the phenotypic expression and in vivo emergence of raltegravir resistance mutations.Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors.Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance.Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.
P2860
Q24628743-ED1EEA20-F824-4F9A-8515-8DAF72928F11Q26851997-67C00B8A-A037-4E19-8805-494456390517Q28480958-04E00B71-FD49-4B5B-988B-7F18BADD3448Q28481393-4987F0D0-E5FD-44A4-8B16-71186BFF295CQ28484064-8F693B05-48A3-4255-BFEB-244FFAD43A48Q30354857-BCBF96F5-77FA-453E-8EC0-A9E459243AF6Q34059896-2CD9356F-72FC-4E22-9979-AEA0164BBB6DQ34363222-F2DCA10E-55C8-45C9-AE71-5BB72E85CAADQ34520239-9A2F61DF-8610-495D-90ED-EBF7A1FDFA60Q34634156-D2C16B9C-B993-41B0-B360-AB38623EEAFFQ34770674-44D22C30-9877-449A-A94F-098657D3BF7AQ35083423-F14764FD-815E-476E-9297-630EFE6B74D7Q35363825-2127DB03-D065-4826-9E38-054EE7C05FADQ36018556-C3CCF041-3FDC-4C90-A60D-C101356822F8Q36353497-31011A1B-F212-43DC-820C-F981F3CEDDDCQ36894960-A2250B71-3CB6-42B1-A555-624A4C847074Q37095708-3231CE0A-E18F-4E7E-8883-C7BD2300A86FQ37124155-C94467C7-94B7-4499-B6D7-C6D6B9222077Q37779774-82AC7B61-D1B2-4890-929C-9AF00318FB76Q38168587-8C2FB439-E95B-48AD-B75B-653AC7D21DB5Q38199659-36B75BDE-BA13-4F61-AE06-01DE92A08190Q38203844-3C4E4D08-97B0-4DF1-8690-EA90CD82818DQ38400895-B7094BB2-635D-4DD3-8898-BE8D417EBAC5Q39103603-B14B4E8F-338C-4E69-B6BA-CD992AE21403Q39562000-1343118A-06A8-4C56-B1DE-4A855EF17051Q39777687-3A3DC566-AAEC-4238-A0E2-EB97B5E964D6Q42183134-581392E0-BEA4-49BF-8905-90E03EC123A0Q42276732-EBA53F65-CC52-407C-A249-E28542988913Q42917410-D72CA6FA-0448-4B2E-9DA0-39978B3B97B1Q46307515-76633795-C138-4075-BA71-7A2BA9E7E12AQ47172282-D53B2F9D-44E3-4C71-953B-3D7BF45F079DQ54520623-A50A3EAB-896C-451E-BED5-164E35962F74
P2860
HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
HIV-1 resistance patterns to i ...... ltegravir-containing regimens.
@en
HIV-1 resistance patterns to i ...... ltegravir-containing regimens.
@nl
type
label
HIV-1 resistance patterns to i ...... ltegravir-containing regimens.
@en
HIV-1 resistance patterns to i ...... ltegravir-containing regimens.
@nl
prefLabel
HIV-1 resistance patterns to i ...... ltegravir-containing regimens.
@en
HIV-1 resistance patterns to i ...... ltegravir-containing regimens.
@nl
P2093
P356
P1476
HIV-1 resistance patterns to i ...... ltegravir-containing regimens.
@en
P2093
Bernard Masquelier
Daniel da Silva
Didier Neau
Dominique Breilh
Guerric Anies
Hervé Fleury
Kurt Van Baelen
Liesbeth Van Wesenbeeck
Michel Dupon
Philippe Morlat
P304
P356
10.1093/JAC/DKQ099
P407
P577
2010-04-12T00:00:00Z